{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-023200","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-07-09T20:09:56+00:00","discovered_at":"2026-07-09T20:11:00.864208+00:00","generated_at":"2026-07-09T20:11:11.263335+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CervoMed completes enrollment in Phase 2a study of neflamapimod for nfvPPA","bullets":["Enrolled 25 participants; interim biomarker data to be presented at CTAD conference Nov 16-19, 2026.","First clinical data expected in Q1 2027; study includes 24-week treatment plus 12-week placebo-controlled extension.","Nature Neuroscience publication shows p38α inhibition rescues axonal transport deficits in tau-related FTD models.","No approved treatments for nfvPPA in US or EU; neflamapimod granted Orphan Drug Designation for FTD in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-023200","json":"https://secwatch.observer/filing/0001437749-26-023200.json","markdown":"https://secwatch.observer/filing/0001437749-26-023200.md","text":"https://secwatch.observer/filing/0001437749-26-023200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926023200/0001437749-26-023200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926023200/crvo20260709_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T20:11:11.263335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}